|
1
|
Arora S, Bhardwaj A, Srivastava SK, Singh
S, McClellan S, Wang B and Singh AP: Honokiol arrests cell cycle,
induces apoptosis, and potentiates the cytotoxic effect of
gemcitabine in human pancreatic cancer cells. PLoS One.
6:e215732011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Niedergethmann M, Alves F, Neff JK, et al:
Gene expression profiling of liver metastases and tumour invasion
in pancreatic cancer using an orthotopic SCID mouse model. Br J
Cancer. 97:1432–1440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar
|
|
4
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen J, Stass SA and Jiang F: MicroRNAs as
potential biomarkers in human solid tumors. Cancer Lett.
329:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
9
|
Wu W, Lin Z, Zhuang Z and Liang X:
Expression profile of mammalian microRNAs in endometrioid
adenocarcinoma. Eur J Cancer Prev. 18:50–55. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rauhala HE, Jalava SE, Isotalo J, et al:
miR-193b is an epigenetically regulated putative tumor suppressor
in prostate cancer. Int J Cancer. 127:1363–1372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu C, Liu S, Fu H, et al: MicroRNA-193b
regulates proliferation, migration and invasion in human
hepatocellular carcinoma cells. Eur J Cancer. 46:2828–2836. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li XF, Yan PJ and Shao ZM: Downregulation
of miR-193b contributes to enhance urokinase-type plasminogen
activator (uPA) expression and tumor progression and invasion in
human breast cancer. Oncogene. 28:3937–3948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu H, Li S, Liu J and Ni B: MicroRNA-193b
modulates proliferation, migration, and invasion of non-small cell
lung cancer cells. Acta Biochim Biophys Sin (Shanghai). 44:424–430.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ikeda Y, Tanji E, Makino N, Kawata S and
Furukawa T: MicroRNAs associated with mitogen-activated protein
kinase in human pancreatic cancer. Mol Cancer Res. 10:259–269.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: MiR-Base: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar
|
|
18
|
Chen J, Zhang X, Lentz C, Abi-Daoud M,
Pare GC, Yang X, et al: miR-193b regulates mcl-1 in melanoma. Am J
Pathol. 176:2162–2168. 2011. View Article : Google Scholar
|
|
19
|
Tahiri A, Leivonen SK, Lüders T, et al:
Deregulation of cancer-related miRNAs is a common event in both
benign and malignant human breast tumors. Carcinogenesis. 35:76–85.
2014. View Article : Google Scholar
|
|
20
|
Zhou H, Wang K, Hu Z and Wen J: TGF-β1
alters microRNA profile in human gastric cancer cells. Chin J
Cancer Res. 25:102–111. 2013.
|
|
21
|
Cheung TH, Man KN, Yu MY, et al:
Dysregulated microRNAs in the pathogenesis and progression of
cervical neoplasm. Cell Cycle. 11:2876–2884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie C, Jiang XH, Zhang JT, et al: CFTR
suppresses tumor progression through miR-193b targeting urokinase
plasminogen activator (uPA) in prostate cancer. Oncogene.
32:2282–2291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Feilotter HE, Pare GC, et al:
MicroRNA-193b represses cell proliferation and regulates cyclin D1
in melanoma. Am J Pathol. 176:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rana S, Maples PB, Senzer N and Nemunaitis
J: Stathmin 1: a novel therapeutic target for anticancer activity.
Expert Rev Anticancer Ther. 8:1461–1470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Belletti B and Baldassarre G: Stathmin: a
protein with many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Targets. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mistry SJ and Atweh GF: Role of stathmin
in the regulation of the mitotic spindle: potential applications in
cancer therapy. Mt Sinai J Med. 69:299–304. 2002.PubMed/NCBI
|
|
27
|
Ke B, Wu LL, Liu N, Zhang RP, Wang CL and
Liang H: Overexpression of stathmin 1 is associated with poor
prognosis of patients with gastric cancer. Tumour Biol.
34:3137–3145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tamura K, Yoshie M, Miyajima E, Kano M and
Tachikawa E: Stathmin regulates hypoxia-inducible factor-1α
expression through the mammalian target of rapamycin pathway in
ovarian clear cell adenocarcinoma. ISRN Pharmacol. 2795932013.
View Article : Google Scholar
|
|
29
|
Jiang L, Chen Y, Chan CY, et al:
Down-regulation of stathmin is required for TGF-beta inducible
early gene 1 induced growth inhibition of pancreatic cancer cells.
Cancer Lett. 274:101–108. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Kuramitsu Y, Ueno T, et al:
Proteomic differential display identifies upregulated vinculin as a
possible biomarker of pancreatic cancer. Oncol Rep. 28:1845–1850.
2012.PubMed/NCBI
|
|
31
|
Reichel CA, Kanse SM and Krombach F: At
the interface of fibrinolysis and inflammation: the role of
urokinase-type plasminogen activator in the leukocyte extravasation
cascade. Trends Cardiovasc Med. 22:192–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cantero D, Friess H, Deflorin J, et al:
Enhanced expression of urokinase plasminogen activator and its
receptor in pancreatic carcinoma. Br J Cancer. 75:388–395. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He X, Zheng Z, Li J, et al: DJ-1 promotes
invasion and metastasis of pancreatic cancer cells by activating
SRC/ERK/uPA. Carcinogenesis. 33:555–562. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saldanha RG, Xu N, Molloy MP, Veal DA and
Baker MS: Differential proteome expression associated with
urokinase plasminogen activator receptor (uPAR) suppression in
malignant epithelial cancer. J Proteome Res. 7:4792–4806. 2008.
View Article : Google Scholar
|
